NCT01003158View on ClinicalTrials.gov

Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
NeoplasmsMetastatic CancerBreast Cancer
Interventions
DRUG

AZD8931

Tablet Oral bid

DRUG

Paclitaxel

IV once weekly for 3 weeks followed by a week off

Trial Locations (1)

Unknown

Research Site, Osaka

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT01003158 - Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients. | Biotech Hunter | Biotech Hunter